Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013

References

• Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report—UNAIDS report on the global AIDS epidemic 2012. UNAIDS; 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf 2012 (accessed 26 December 2013).
   Google Scholar
• Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385–93.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Tatsioni A, Abrams EJ, Bulterys M, Coombs RW, Goedert JJ, et al. Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis. AIDS 2004;18: 99–108.
   PubMed Web of Science ®Google Scholar
• Tubiana R, Le Chenadec J, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load < 500 copies/ml at delivery: a case–control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010;50:585–96.
   PubMed Web of Science ®Google Scholar
• Boer K, England K, Godfried MH, Thorne C, Newell ML, Mahdavi S, et al. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010; 11:368–78.
   PubMed Web of Science ®Google Scholar
• Mark S, Murphy KE, Read S, Bitnun A, Yudin MH. HIV mother-to-child transmission, mode of delivery, and duration of rupture of membranes: experience in the current era. Infect Dis Obstet Gynecol 2012;2012:267969.
   PubMedGoogle Scholar
• Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996;175:661–7.
   PubMed Web of Science ®Google Scholar
• Coll O, Suy A, Hernandez S, Pisa S, Lonca M, Thorne C, et al. Prenatal diagnosis in human immunodeficiency virus-infected women: a new screening program for chromosomal anomalies. Am J Obstet Gynecol 2006; 194:192–8.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, et al. Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales French perinatal cohort. Am J Obstet Gynecol 2009;200:160.e1–9.
   Google Scholar
• Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173–80.
   PubMed Web of Science ®Google Scholar
• Tariq S, Townsend CL, Cortina-Borja M, Duong T, Elford J, Thorne C, et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009. J Acquir Immune Defic Syndr 2011;57:326–33.
   PubMed Web of Science ®Google Scholar
• Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012;366:2368–79.
   PubMed Web of Science ®Google Scholar
• The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340: 977–87.
   PubMed Web of Science ®Google Scholar
• European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458–65.
   PubMed Web of Science ®Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother- to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008;22:973–81.
   PubMed Web of Science ®Google Scholar
• Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS 2008;22:289–99.
   PubMed Web of Science ®Google Scholar
• Briand N, Jasseron C, Sibiude J, Azria E, Pollet J, Hammou Y, et al. Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000–2010. Am J Obstet Gynecol 2013;209:335.e1–335.e12.
   Web of Science ®Google Scholar
• Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007;21:501–7.
   PubMed Web of Science ®Google Scholar
• Mayaud P, Nagot N, Konate I, Ouedraogo A, Weiss HA, Foulongne V, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008;84:332–7.
   Google Scholar
• O’Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School Working Group on Mother–Child Transmission of HIV. AIDS 2000;14:441–8.
   PubMed Web of Science ®Google Scholar
• The Antiretroviral Pregnancy Registry interim report for 1 January 1989 through 31 January 2013. Wilmington, NC: Antiretroviral Pregnancy Registry; 2013. Available at: http://www.APRegistry.com (accessed 28 August 2013).
   Google Scholar
• Best BM, Capparelli EV. Implications of gender and pregnancy for antiretroviral drug dosing. Curr Opin HIV AIDS 2008;3:277–82.
   PubMedGoogle Scholar
• Burchett S, Best B, Mirochnick M, Hu C, Capparelli E, Holland D, et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Abstract 738b. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 2007.
   Google Scholar
• von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006; 62:552–9.
   PubMed Web of Science ®Google Scholar
• Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr 2010;55: 345–50.
   PubMed Web of Science ®Google Scholar
• Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012;59:245–52.
   PubMed Web of Science ®Google Scholar
• Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med 2011;12:257–8.
   PubMed Web of Science ®Google Scholar
• Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006;20:1931–9.
   PubMed Web of Science ®Google Scholar
• Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002;16:2081–3.
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21:2409–15.
   PubMed Web of Science ®Google Scholar
• Conradie F, Zorilla C, Josipovic D, Botes M, Osiyemi Y, Gomez M, et al. The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182. Abstract LBPEB06. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009.
   Google Scholar
• Mirochnick M, Stek A, Capparelli E, Best B, Rossi S, Burchett S, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Abstract 941. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
   Google Scholar
• Ripamonti D, Cattaneo D, d’Avolio A, Simiele M, Bonora S, Strobelt N, et al. Steady state pharmacokinetic of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery. Abstract 907. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 2010.
   Google Scholar
• Zorrilla C, Wright R, Osiyemi O, Yasin S, Baugh B, Brown K, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med 2014;15:50–6.
   PubMed Web of Science ®Google Scholar
• Croci L, Trezzi M, Allegri MP, Carli T, Chigiotti S, Riccardi MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol 2012;68:1231–2.
   PubMed Web of Science ®Google Scholar
• McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010;24:2416–8.
   PubMed Web of Science ®Google Scholar
• Westling K, Pettersson K, Kaldma A, Naver L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS 2012;26:714–7.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998;178: 368–74.
   PubMed Web of Science ®Google Scholar
• Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010;65:2050–2.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002, 16:889–93.
   PubMed Web of Science ®Google Scholar
• Weizsaecker K, Kurowski M, Hoffmeister B, Schurmann D, Feiterna-Sperling C. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS 2011;22:294–5.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009;51:546–53.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007;21:1899–907.
   PubMed Web of Science ®Google Scholar
• Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004; 37:1577–80.
   PubMed Web of Science ®Google Scholar
• Jones A, Talameh J, Patterson K, Rezk N, Prince H, Kashuba A. First-dose and steady-state pharmacokinetics (PK) of raltegravir (RAL) in the genital tract (GT) of HIV uninfected women. Abstract O_06. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands, 2009.
   Google Scholar
• Dalgaard LS, Sogaard OS, Jensen-Fangel S, Larsen CS, Sonnerborg A, Ostergaard L. Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study. Scand J Infect Dis 2012;44:108–14.
   PubMed Web of Science ®Google Scholar